[Federal Register Volume 59, Number 105 (Thursday, June 2, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-13398]


[[Page Unknown]]

[Federal Register: June 2, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF JUSTICE
 

Manufacturer of Controlled Substances; Application

    Pursuant to section 1301.43(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 15, 1994, Radian 
Corporation, 8501 Mopac Blvd., P.O. Box 201088, Austin, Texas 78720, 
made application to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the basic classes of controlled 
substances listed below:

------------------------------------------------------------------------
                                                              Schedule  
------------------------------------------------------------------------
Drug:                                                                   
Cathinone (1235)..........................................  I           
Methcathinone (1237)......................................  I           
Aminorex (1585)...........................................  I           
4-Methylaminorex (cis isomer) (1590)......................  I           
Methaqualone (2565).......................................  I           
Ibogaine (7260)...........................................  I           
Lysergic acid diethylamide (7315).........................  I           
Tetrahyrocannabinols (7370)...............................  I           
Mescaline (7381)..........................................  I           
3,4-Methylenedioxyamphetamine (7400)......................  I           
3,4-Methylenedioxy-N-ethylamphetamine (7404)..............  I           
3,4-Methylenedioxymethamphetamine (7405)..................  I           
4-Methoxyamphetamine (7411)...............................  I           
Heroin (9200).............................................  I           
Normorphine (9313)........................................  I           
Acetylmethadol (9601).....................................  I           
3-Methylfentanyl (9813)...................................  I           
Amphetamine (1100)........................................  II          
Methamphetamine (1105)....................................  II          
Methylphenidate (1724)....................................  II          
Amobarbital (2125)........................................  II          
Pentobarbital (2270)......................................  II          
Secobarbital (2315).......................................  II          
Phencyclidine (7471)......................................  II          
Oxycodone (9143)..........................................  II          
Hydromorphone (9150)......................................  II          
Benzoylecgonine (9180)....................................  II          
Hydrocodone (9193)........................................  II          
Meperidine (9230).........................................  II          
Methadone (9250)..........................................  II          
Morphine (9300)...........................................  II          
Oxymorphone (9652)........................................  II          
Alfentanil (9737).........................................  II          
Sufentanil (9740).........................................  II          
Fentanyl (9801)...........................................  II          
------------------------------------------------------------------------


    The firm plans to manufacture deuterated material for use in exempt 
products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the above application and may also file a written 
request for a hearing thereon in accordance with 21 CFR 1301.54 and in 
the form prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, United States Department of 
Justice, Washington, DC 20537, Attention: DEA Federal Register 
Representative (CCR), and must be filed no later than July 5, 1994.

    Dated: May 23, 1994.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 94-13398 Filed 6-1-94; 8:45 am]
BILLING CODE 4410-09-M